Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jimmy Dhillon
Institutions:
Rutgers, The State University of New Jersey,
University of Maryland, Baltimore
Observed institutions:
Rutgers, The State University of New Jersey,
University of Maryland, Baltimore
ORCID:
0009-0003-5237-5912
Observed ORCID:
0009-0003-5237-5912
OpenAlex ID:
A5005462648
Vitiligo: From Mechanisms of Disease to Treatable Pathways
2024
·
Gaurav N. Pathak
, Isabella J. Tan
, et al.
·
Skin Health and Disease
·
30
PDF
Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis
2024
·
Gaurav N. Pathak
, Emily Wang
, et al.
·
Annals of Pharmacotherapy
·
22
Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence
2024
·
Gaurav N. Pathak
, Priya Agarwal
, et al.
·
The Journal of Dermatology
·
18
Climate change, harmful algal blooms, and cutaneous disease
2025
·
Jimmy Dhillon
, Eva Rawlings Parker
·
JAAD reviews.
·
13
PDF
Roflumilast and the Changing Landscape of Seborrheic Dermatitis Treatment
2025
·
Jimmy Dhillon
, Aryan Mahajan
, et al.
·
Annals of Pharmacotherapy
·
3
Therapeutic Interventions for Apocrine, Eccrine, and Pseudo Chromhidrosis: An Overview of the Current Literature
2025
·
Jimmy Dhillon
, Madeline Tchack
, et al.
·
Skin Research and Technology
·
1
PDF
High-dimensional flow cytometry of peripheral blood mononuclear cells in prurigo nodularis reveals dysregulation of IL-6 family cytokines
2026
·
Kevin K. Lee
, Kavita Vats
, et al.
·
Journal of Investigative Dermatology
Beremagene geperpavec (B-VEC): the first topical gene therapy for dystrophic epidermolysis bullosa
2026
·
Emily Wang
, Jimmy Dhillon
, et al.
·
Archives of Dermatological Research
76154 Characterizing vaccine-induced dermatomyositis: a retrospective analysis of the Vaccine Adverse Event Reporting System (VAERS)
2026
·
Jimmy Dhillon
, Gaurav Pathak
, et al.
·
Journal of the American Academy of Dermatology
76171 Public interest in topical treatments for vitiligo following the U.S. Food and Drug Administration approval for ruxolitinib: a Google Trends analysis
2026
·
Jimmy Dhillon
, Gaurav Pathak
, et al.
·
Journal of the American Academy of Dermatology
76121 Racial differences in non-disease specific causes of mortality in acral lentiginous melanoma: a national database study
2026
·
Jimmy Dhillon
, Babar Rao
·
Journal of the American Academy of Dermatology
63928 Relative Sunscreen Demand Indices can Aid in the Identification of Sunscreen Deserts in the United States
2025
·
Jimmy Dhillon
, Bianca Sanabria
, et al.
·
Journal of the American Academy of Dermatology
61806 Pemphigus Relapse: Insights on pathogenesis, factors, and agents associated with disease recurrence
2025
·
Gaurav Pathak
, Priya Agarwal
, et al.
·
Journal of the American Academy of Dermatology
63959 Beremagene Geperpavec is the First FDA-Approved Topical Gene Therapy for Dystrophic Epidermolysis Bullosa
2025
·
Emily Wang
, Jimmy Dhillon
, et al.
·
Journal of the American Academy of Dermatology
Socioeconomic factors associated with the development of localized scleroderma: a cross-sectional study
2025
·
Jimmy Dhillon
, Anushka Pande
, et al.
·
Archives of Dermatological Research
Identifying potential sunscreen deserts in the United States using relative sunscreen demand indices
2025
·
Jimmy Dhillon
, Bianca Sanabria
, et al.
·
Archives of Dermatological Research
Public interest in benzoyl peroxide: A Google Trends analysis
2024
·
Isabella J. Tan
, Bianca Sanabria
, et al.
·
Journal of Cosmetic Dermatology
PDF
Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)
2024
·
Gaurav N. Pathak
, Anurag N. Pathak
, et al.
·
Journal of Dermatological Treatment
PDF
Show more works
View as search
Works count:
18
Citation count:
87
H-index:
4
I10-index:
4
Year
Topic
Type